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Abstract
Background: Inflammatory cytokines play a crucial role in coronary artery disease (CAD). We investigated the 
association between 48 coding and three non-coding single nucleotide polymorphisms (SNPs) from 35 inflammatory 
genes and the development of CAD, using a large discordant sibship collection (2699 individuals in 891 families).
Methods: Family-based association tests (FBAT) and conditional logistic regression (CLR) were applied to single SNPs 
and haplotypes and, in CLR, traditional risk factors of CAD were adjusted for.
Results: An association was observed between CAD and a common three-locus haplotype in the interleukin one (IL-1) 
cluster with P = 0.006 in all CAD cases, P = 0.01 in myocardial infarction (MI) cases and P = 0.0002 in young onset CAD 
cases (<50 years). The estimated odds ratio (OR) per copy of this haplotype is 1.21 (95% confidence interval [95CI] = 
1.04 - 1.40) for CAD; 1.30 (95CI = 1.09 - 1.56) for MI and 1.50 (95CI = 1.22 - 1.86) for young onset CAD. When sex, 
smoking, hypertension and hypercholesterolaemia were adjusted for, the haplotype effect remained nominally 
significant (P = 0.05) in young onset CAD cases, more so (P = 0.002) when hypercholesterolaemia was excluded. As 
many as 82% of individuals affected by CAD had hypercholesterolaemia compared to only 29% of those unaffected, 
making the two phenotypes difficult to separate.
Conclusion: Despite the multiple hypotheses tested, the robustness of family design to population confoundings and 
the consistency with previous findings increase the likelihood of true association. Further investigation using larger 
data sets is needed in order for this to be confirmed.
See the related commentary by Keavney: http://www.biomedcentral.com/1741-7015/8/6
Background
Coronary atherosclerosis is predominantly an asymptom-
atic process that progresses over the course of a lifetime.
Arterial inflammation is central to plaque progression and
plaque rupture with atherosclerotic lesions established as
active sites of inflammation [1]. In particular, cytokines
appear to coordinate the development of atherosclerosis
leading to the formation of complex atherosclerotic
plaques. These, in turn, can trigger acute thromboembolic
complications such as myocardial infarction (MI) and the
rupture/repair process that promotes the progression of
luminal narrowing [2]. Furthermore, those lesions convey-
ing the greatest risk to the individual are characterized by a
higher level of inflammation. Coronary atherosclerosis and
its complications are a complex disorder resulting from the
combined effects of multiple environmental and genetic
factors. Whilst most traditional risk factors for coronary
artery disease (CAD) are themselves heritable, a family his-
tory remains an independent predictor of this condition
[1,2]. The aim of this study was to evaluate individual poly-
morphisms and haplotypes in inflammatory genes for asso-
ciation with an increased predisposition to CAD. In total,
51 single nucleotide polymorphisms (SNPs) were analysed
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sibships recruited across the UK in the Genetic Risk of
Acute Coronary Events (GRACE) study.
Methods
Clinical methods
The study was approved by the Multicentre (MREC) and
Local Research Ethics Committees (LRECs) throughout the
UK. The details of the recruitment process can be found in
the Additional File 1. Premature CAD was defined as a val-
idated MI, percutaneous transluminal coronary angioplasty
(PTCA), coronary artery bypass surgery (CABG) or angina
(exercise test positive or angiogram showing at least one
lesion >50%) before the age of 66. Hypercholesterolaemia
was considered as either being on lipid lowering therapy or
having total cholesterol greater than 4.9 mmol.l-1 for indi-
viduals with a previous MI or greater than 5.2 mmol/l for
individuals with other affected phenotypes (PTCA, CABG
or angina) and unaffected individuals. Hypertension was
either being on therapy or a blood pressure greater than
150/90 mmHg.
Genotyping
Fifty SNPs and one insertion/deletion, mainly located in
coding regions of 35 inflammatory genes, were genotyped
(48 polymorphisms from coding regions and three from the
introns). The primer mix and all other necessary compo-
nents for the SNP genotyping were provided by Roche
Molecular Systems (Pleasanton, USA). Characteristics of
the polymorphisms are shown in the Additional File 2.
DNA extraction and storage was performed using the
PUREGENE® DNA extraction kit (available from Gentra
Systems, MN, USA). A pooled polymerase chain reaction
(PCR) amplified the chosen targets from 50 ng of genomic
DNA to produce biotin labelled products. These products
were then hybridized with sequence specific oligonucle-
otide probes immobilized in a linear array. A series of
development stages enabled detection of hybridization
between probe and PCR product thus allowing identifica-
tion of genotypes (homozygous wild, homozygous mutant,
heterozygote). The processed strip was then scanned and
genotypes were assigned by StripScan software (Roche
Molecular Systems) [3] providing a semi-automated read-
ing of the data assigning genotypes.
Statistical analyses
Family relationships were validated using the Graphical
Representation of Relationships (GRR) and RELATIVE
programs [4,5] based on the 51 polymorphisms from this
study plus 65 additional SNPs (analysis details in the Addi-
tional File 3). Allele frequencies were estimated using the
program MENDEL which accounts for family relationships
[6] and Hardy-Weinberg equilibrium was tested for each
SNP using a goodness-of-fit test. The primary analysis was
a test of association in presence of linkage between CAD
and each individual SNP using the family-based association
test (FBAT) [7]. We used the version of this test that
employs empirical variance to account for residual familial
correlation [8] (program FBAT 2.0.2C, option -e). An addi-
tive mode of inheritance was assumed. The analysis was
repeated in two subsets of the data: (1) all cases affected
with MI and their siblings and (2) all cases of CAD before
the age of 50 and their siblings (see details in the Additional
File 3). For genes or regions where two or more polymor-
phisms were in linkage disequilibrium (LD), haplotype
analysis was also carried out in FBAT.
The haplotypes showing the highest evidence of associa-
tion were further analysed using simple conditional logistic
regression (CLR) in STATA [9], subsequently adding in
clinical covariates. Robust variance was used to account for
correlation between family members in CLR [10,11]. Hap-
lotypes were inferred using the program HAPLORE [12].
As parents were not genotyped, there was some uncertainty
in haplotype assignment. This uncertainty was accounted
for in CLR by using a weighting approach originally
designed for unrelated cases and controls [13] and adapted
here to family data (see details in the Additional File 3).
After identifying a haplotype associated with CAD, we
used unconditional logistic regression to assess whether the
same haplotype predicts hypercholesterolaemia, the most
predominant clinical risk factor for CAD in our dataset.
Results
Family structures and effects of clinical risk factors
The initial data set consisted of 2870 individuals from 930
families. As a result of relationship checking, a total of 41
families were discarded - mainly because reported siblings
were found to be more likely half-siblings. In addition, two
families were each split into two, leaving a final sample
size of 2699 persons from 891 families. The structure of the
families included in this study is detailed in Table 1. The
median age of disease onset was 50 years (range 21-66) and
69% of affected individuals had a MI as the index event.
The median age of unaffected individuals was 57 years
(range 35-85) and intra-family comparisons of ages
revealed that over 80% of unaffected siblings had surpassed
the age at which their affected siblings had their events.
Clinical characteristics of the study sample are shown in
Table 2.
Considered individually, each of the traditional risk fac-
tors of CAD [male gender, diabetes, hypertension, hyperc-
holesterolaemia, cigarette smoking and body mass index
(BMI)] has a highly significant effect on disease risk. When
all these factors are included in the model jointly, male gen-
der, hypertension, cigarette smoking and hypercholestero-
laemia still show a highly significant effect on CAD, whilst
diabetes mellitus has a borderline effect and BMI was not
associated with CAD (Table 2).
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The results of SNP by SNP analysis are shown in Table 3.
Results are reported only for SNPs that were in Hardy-
Weinberg equilibrium and for which we had at least 50
informative families (the average number of informative
families was 345). Associations with CAD significant at
5% level were found for polymorphisms in interleukin 9
[(IL9) C4244T, P = 0.01], nitric oxide synthase 3 [(NOS3)
A498G, P = 0.05], complement component 5 [(C5)
A2416G, P = 0.04], interleukin 4 receptor [(IL4R T1682C,
P = 0.01 and A1902G, P = 0.04] and eotaxin [(SCYA11)
G361A, P = 0.04]. In the subsets of MI cases and those with
younger CAD onset (<50 years) the associations with C5
(A2416G) remained (MI only P = 0.006; <50 years P =
0.04) and additional significant associations were observed
with interleukin 1 alpha (IL1α) C549T (MI only P = 0.02;
<50 years P = 0.02).
Haplotype analysis
More than one SNP were genotyped within 13 genes and
one gene cluster (IL1α-IL1β). Table 4 shows the genes or
gene cluster where any haplotype was significantly associ-
ated with CAD, CAD before 50 years or MI at the nominal
5% level using FBAT. The LD (measured with D') between
adjacent SNPs is also shown along with their physical posi-
tion from dbSNP build 128. The most significantly associ-
ated haplotype was found in the IL1 cluster (CCC
haplotype, frequency of 41% in the total sample), which
was found at increased frequency in all CAD cases (P =
0.006), MI cases (P = 0.01) and young CAD cases (P =
0.0002), although the overall haplotype effect only reached
the 5% significance level in early-onset CAD cases (P =
0.02, with 7 degrees of freedom). In NOS3 gene, there was
a significant protective effect of the AT haplotype (fre-
quency 11%) in overall CAD (single haplotype P = 0.009
and overall test P = 0.04) and in MI (single haplotype P =
Table 1: Structure of families included in the study.
No. of affecteds No. of unaffecteds No. of families with
CAD CAD before 50 years* MI †
1 1 164 149 122
1 2 439 235 362
1 >2 49 38 39
2 1 158 46 78
2 2 42 15 23
2 >2 18 6 14
≥ 3 ≥1 21 4 11
Total families 891 493 660
Total affecteds 1154 568 802
Total unaffecteds 1545 855 1204
* In this setting, individuals affected after 50 years were considered as unphenotyped
† For this trait coding, individuals free of myocardial infarction (MI) but affected by other forms of coronary artery disease (CAD) were consid-
ered unphenotyped.
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dence of haplotype association in this gene in younger dis-
ease onset. Other haplotypes with nominally significant
effects were found in IL4R and SCYA11 (Table 4).
IL1 haplotype effect estimation
Using an additive model with no covariate adjustment in
weighted CLR, each copy of IL1-CCC haplotype confers an
increase in risk of CAD with estimated odds ratio (OR) of
1.21 [95% confidence interval (95 CI) = 1.04-1.40, P =
0.01] in the total sample. For young-onset cases, the esti-
mated OR was 1.50 (95 CI = 1.22 - 1.86, P = 0.0001) and
for MI the OR was 1.30 (95 CI = 1.09 - 1.56, P = 0.003).
The overall significance level of all haplotypes (7df) was
0.28 in the whole sample, 0.18 for MI only and 0.02 in the
affecteds before age 50. When tested jointly with four clini-
cal covariates (hypercholesterolaemia, hypertension, smok-
ing and sex), the effect of haplotype IL1-CCC on CAD was
no longer significant in the whole sample (OR = 1.07, P =
0.57) nor in those affected by MI (OR = 1.26, P = 0.07), but
it was nominally significant in younger cases (<50 years
OR = 1.39, P = 0.05). No significant interaction was found
between IL1-CCC haplotype and any of the covariates.
The most potent predictor of increased risk of disease in
our population was hypercholesterolaemia (see Table 2).
When it was excluded from the multivariable analysis, the
effect of haplotype IL1-CCC in the whole sample was sig-
nificant (OR = 1.22, P = 0.05), and was more so in those
with younger onset disease (OR = 1.53, P = 0.002, see
Table 5). This indicates a possible relationship between the
haplotype and hypercholesterolaemia itself. In order to test
this, a simple unconditional logistic regression analysis was
carried out on the whole study population and stratifying by
CAD, using hypercholesterolaemia as the trait of interest
with IL1-CCC haplotype as predictor. In the whole dataset,
the estimated OR of having hypercholesterolaemia was
1.15 (95 CI = 1.03 - 1.29, unadjusted P = 0.01) per copy of
haplotype IL1-CCC. This was comparable to the OR of
developing CAD per copy the same haplotype using uncon-
ditional logistic regression (OR = 1.21, 95 CI = 1.02 - 1.43,
unadjusted P = 0.02). The haplotype effect on hypercholes-
terolaemia was of the same magnitude in subjects affected
and unaffected by CAD, although not significant in these
smaller subsets (OR = 1.10, 95 CI = 0.88-1.37 and OR =
1.13, 95 CI = 0.96-1.33, respectively). This result suggests
Table 2: Clinical characteristics of the study sample.
Unaffected Affected




Total sample 1545 (100) 1154 (100) - -
Male sex 630 (40.8) 873 (75.7) <0.0001 4.71 (3.65, 6.08)
Diabetes mellitus 62 (4.0) 117 (10.1) <0.0001 1.63 (1.00, 2.66)
Hypertension 391 (25.3) 522 (45.2) <0.0001 1.99 (1.52, 2.60)
Hypercholesterolae-
mia
454 (29.4) 945 (81.9) <0.0001 10.70 (8.11, 14.11)





0.0002 1.00 (0.97, 1.04)
* Univariate conditional logistic regression for binary factors and linear regression clustered by family for body mass index (BMI)
† Odds ratio (OR) and 95% confidence intervals from multivariable conditional logistic regression analysis including all six factors
SD: standard deviation
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Chromosome Gene SNP RS number MAF P-value *
1p32-p31 VCAM1 T707C 1041163 0.16 0.39
1q21-24 SELP G40A 6131 0.18 0.84
G75271T 6133 0.14 0.67
1q22-q25 SELE A153C 5361 0.11 0.33
1q31-32 IL10 C8700A 1800872 0.24 0.29
2q12-q21 IL1α C549T 1800587 0.31 0.08
2q14 IL1β C4336T 1143634 0.26 0.58
C1423T 16944 0.34 0.49
2q33 CTLA4 C875T 5742909 0.10 0.34
2q33 CTLA4 A1241G 231775 0.40 0.68
3p21 CCR2 G46295A 1799864 0.08 0.88
3p21 CCR5 Wt/del 580-611 333 0.14 0.72
G59029A 1799987 0.44 0.33
3p21.3 CCR3 C320T 5742906 0.01 - †
3p26-p24 IL5RA G482A 2290608 0.28 0.10
4q12-q13 GC G35706T 7041 0.44 0.50
GC C35717A 4588 0.29 0.21
5q22-32 CD14 C2232T 2569190 0.47 0.63
5q23-q31 IL4 C582T 2243250 0.14 0.66
5q31 IL13 C4045T 1295686 0.20 0.78
5q31 TCF7 C883A 5742913 0.12 0.35
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5q31.1 CSF2 T2600C 244656 0.22 0.16
5q31-q32 ADRB2 A1633G 1042713 0.37 0.91
C1666G 1042714 0.42 0.37
C2078T 1800888 0.02 - †
5q31-q35 IL9 C4244T 2069885 0.13 0.01 (T)
5q35 LTC4S A620C 730012 0.31 0.22
6p21.3 LTA A1069G 909253 0.39 0.60
TNF G3787A 1800629 0.21 0.34
G3857A 361525 0.07 0.99
7p21-p15 IL6 G589C 1800796 0.06 0.33
G987C 1800795 0.43 0.38
7q35-q36 NOS3 A498G 1800779 0.40 0.05 (G)
G7002T 1799983 0.36 0.67
9q32-q34 C5 A2416G 17611 0.44 0.04 (G)
10q11.1 SDF1 G880A 1801157 0.20 0.84
11q11-qter UGB G587A 3741240 0.36 0.65
11q13 FCERB1 A7297G 569108 0.03 0.48
12q13.1 VDR T12022C 2228570 0.40 0.77
G45082A 1544410 0.42 0.61
16p11.2-p12.1 IL4R A398G 1805010 0.46 0.56
T1682C 1805015 0.20 0.01 (C)
Table 3: Tests of association between SNPs and CAD using FBAT. (Continued)
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through increasing the risk of hypercholesterolaemia,
although the high correlation between hypercholesterolae-
mia and CAD in our study makes this difficult to evaluate.
Discussion
We present here the results of an association analysis of
CAD with multiple inflammatory genes in one of the UK's
largest discordant sibship studies. This family-based cohort
avoids the potential bias of population stratification and
admixture that may affect even a well designed case-control
study [14]. The haplotype analysis maximized the use of
family information and accommodated phase uncertainty.
Our strongest finding was a suggested association with a
common haplotype in the interleukin 1 gene cluster (IL1-
CCC, see Table 4), particularly in those individuals with
younger onset CAD. The per-copy OR for CAD was 1.21
(unadjusted P = 0.01), rising to 1.50 in younger affecteds
(unadjusted single haplotype test P = 0.0001 and overall
test P = 0.02). The effect of this haplotype on early-onset
disease risk remained significant after adjusting for covari-
ates other than hypercholesterolaemia (OR = 1.53, P =
0.002, Table 5). However, including hypercholesterolaemia
in the model greatly reduced the estimated effect. The effect
of IL1-CCC on hypercholesterolaemia was found to be of
similar magnitude as on CAD itself, suggesting that IL1-
CCC may actually increase the risk to CAD through
increasing the risk of hypercholesterolaemia.
The relationship between hypercholesterolaemia and
CAD is well established. At present, no direct evidence of
correlation between IL-1 and hypercholesterolaemia exists
in man. Mice lacking interleukin-1 receptor antagonist
(IL1RA) display significant derangement of cholesterol
homeostasis in response to an atherogenic diet [15]. Fur-
thermore, studies in hypercholesterolemic mice suggest that
lack of IL-1β or over-expression of IL1RA can partly pro-
tect against atherosclerosis [16]. Accordingly, elevation of
IL-1 is consistently observed in individuals with unstable
CAD and predicts mortality post MI [17]. The use of HMG-
CoA inhibitors (statins), known to reduce lipoprotein levels
and risk of cardiovascular events, has been shown to reduce
mRNA levels of both IL1α and IL1β in peripheral blood
mononuclear cells (PBMCs) [17] providing further evi-
dence of an interplay between IL-1 and hypercholesterolae-
mia.
Ikonomidis et al. [18] have evaluated the immediate and
short-term effects of anakinra, a recombinant IL1 receptor
antagonist, on coronary flow; left ventricular (LV) and
endothelial function and mediators of inflammation. In
patients with rheumatoid arthritis and no evidence of CAD/
ischaemia, anakinra resulted in both an acute and sustained
improvement in left ventricular function, endothelial func-
tion and coronary flow reserve with a reduction in IL-6 and
endothelin-1, compared to placebo/prednisolone. Relatively
small numbers of patients were studied and those with CAD
were specifically excluded. It remains unclear, therefore,
A1902G 1801275 0.25 0.04 (G)
17q11.2-q12 NOS2A C231T 1137933 0.23 0.98
17q21.1-q21.2 SCYA11 G361A 3744508 0.19 0.04 (G)
G1169A 4795895 0.20 0.47
19q13.1 TGFB1 C629T 1800469 0.27 - ‡
19p13.2 ICAM1 A120T 5491 0.001 - ‡
G657A 1799969 0.12 0.43
19p13.3-p13.2 C3 C364G 2230199 0.24 0.39
* In parenthesis after the P-value: the allele associated with an increased disease risk.
† Number of informative families below 50.
‡ Not in Hardy-Weinberg equilibrium.
MAF, minor allele frequency; SNP, single nucleotide polymorphism; CAD, coronary artery disease.
Table 3: Tests of association between SNPs and CAD using FBAT. (Continued)
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Gene SNP Position
*
LD† Hap‡ Freq§ P_CAD P_MI P_CAD50
IL1α C549T 11325943
1
CCC 0.41 0.006 (+) 0.01 (+) 0.0002
(+)
0.78 CCT 0.26 0.60 0.96 0.32
IL1β C4336T 11330686
1
CTC 0.17 0.30 0.06 0.31
0.67 TCC 0.06 0.08 0.30 0.08
IL1β C1423T 11331133
8
TCT 0.04 0.45 - 0.37
CTC 0.03 0.69 - -
TTT 0.02 - - -
CTT 0.01 - - -
All (7df) - 0.13 0.25 0.02
NOS3 A498G 15032087
6
AG 0.50 0.77 0.84 0.63
0.47 GT 0.23 0.24 0.32 0.40
NOS3 G7002T 15032704
4
GG 0.16 0.16 0.11 0.36
AT 0.11 0.009 (-) 0.005 (-) 0.15
All (3df) - 0.04 0.03 0.39
SCYA11 G361A 29637007 GG 0.66 0.05 (+) 0.10 0.02 (+)
1.00 GA 0.18 0.84 0.73 0.29
SCYA11 G1169A 29635559 AG 0.16 0.02 (-) 0.09 0.06
AA 0.00 - - -
All (2df) - 0.05 0.17 0.06
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0.37 GTA 0.33 0.44 0.46 0.63
IL4R T1682C 27281681 GCG 0.11 0.04 (+) 0.24 0.56
1.00 ACG 0.06 0.22 0.49 0.20
IL4R A1902G 27281901 ATG 0.03 0.91 0.60 0.03 (+)
GTG 0.02 - - -
GCA 0.002 - - -
ACA 0.001 - - -
All (7df) - 0.88 0.41 0.17
*Physical position (base pairs) from NCBI dbSNP build 128.
† Absolute value of the linkage disequilibrium (LD) coefficient D' between consecutive single nucleotide polymorphisms (SNPs).
‡ Results only shown for haplotypes having a number of informative families >50.
§Haplotype frequencies estimated in the total sample.
+ (-), Haplotype associated with increased (decreased) disease risk; CAD, coronary artery disease; MI, myocardial infarction; SNP, single nucle-
otide polymorphism.
Table 4: Haplotype association to CAD, CAD before age 50 (CAD50) or MI. (Continued)
whether these findings have any relevance to those with significantly lower IL-1β levels than in non-carriers. How-
CAD/without rheumatoid arthritis. In particular, are the
changes in LV and endothelial function reversible when
ischaemic in aetiology and are the inflamed joints of active
rheumatoid arthritis a prerequisite for anakinra to have an
effect? In animal models, acute anakinra administration
does appear to reduce cardiomyocyte apoptosis and adverse
remodelling [19]. Further clarity is likely to be added by the
Medical Research Council funded ILA HEART study [20]
evaluating anakinra in patients presenting with a MI.
The IL1β polymorphism C1423T has been investigated
previously in relation to CAD, with mixed results. An
excess of CC genotypes was reported in affected individu-
als compared to unaffecteds (22% versus 13%), although
this difference was not significant [21]. Another study [22]
subsequently found no evidence of difference in allele fre-
quencies on this SNP between subjects with angiographi-
cally normal and abnormal coronary arteries. By contrast,
Iacoviello et al. [23] found a significantly reduced risk of
MI and ischaemic stroke at young age (<45 years for men
and <50 for women) in carriers of the T allele after adjust-
ment of the traditional risk factors. They also demonstrated
that mononuclear cells in carriers of the T allele produce
ever, the same T allele was found significantly associated
with increased risk of atherogenesis in subclavian arteries
in a cohort of elderly Japanese [24].
In our study, no association was found between the IL1β
C1423T SNP and CAD, but we did detect an association
with a haplotype containing this SNP. These results suggest
that the SNP itself may not increase the risk of CAD but
may be in strong LD with a causal variant, which may also
partially explain inconsistencies in results across different
studies. It is also possible that it is the haplotype that influ-
ences CAD rather than one nucleotide change. Chen et al.
[25] showed that SNP alleles in IL1β have increased tran-
scriptional activity when combined (into haplotypes) and
suggested that it may be a common feature of gene regula-
tory regions. IL1 gene cluster haplotypes have been found
associated with many diseases, including schizophrenia and
bipolar disorder [26], gastric cancer [27] and psoriatic
arthritis [28]. In the case of CAD, age of onset appears to be
an important factor (our study and [23]).
The IL1α and IL1β genes lie on chromosome 2 about 15
Mb centromeric to the linkage peak found in a large UK
study of sibling pairs affected with CAD [29]. The evidence
Brown et al, BMC Medicine 2010, 8:5
http://www.biomedcentral.com/1741-7015/8/5
Page 10 of 12for linkage in this region was much stronger in the subset of
sibling pairs without hypercholesterolaemia, although when
this covariate was included in the analysis the main linkage
peak shifted slightly further away from the IL1 gene cluster
[30]. It is well known that the highest linkage peak may be
at a considerable distance from the disease-causing locus,
especially when based on relative pair analyses, so it is pos-
sible that the IL1 cluster contributed to the evidence of link-
age.
Our second interesting finding was in the gene NOS3 on
chromosome 7. Many studies have reported an association
between the G7002T SNP in this gene (also referred to as
894G/T or Glu298Asp) and a number of diseases including
CAD/MI [31,32] and essential hypertension [33,34]. How-
ever, most of these studies were based on unrelated case-
control designs with a limited size. While our larger study
does not confirm the association of this SNP with CAD (P
= 0.67, Table 3), we did observe a weak association
between CAD and a promoter region SNP (A498G, P =
0.05, Table 3) whilst a haplotype spanning the two SNPs
showed a stronger association (single haplotype test P =
0.009 for CAD and P = 0.005 for MI, overall haplotype test
P = 0.04 for CAD and P = 0.03 for MI, Table 4). The AT
haplotype appears to reduce the risk of CAD and MI,
although this was not confirmed in patients affected at
younger age. Although the polymorphism G7002T changes
the protein sequence (Glu298Asp), its actual functional sig-
nificance is not well understood [33] and our results suggest
again that a haplotype or an untyped SNP may be of rele-
vance.
Other SNPs or haplotype associations marginally signifi-
cant in this study were found in IL9, C5, IL4R and SCYA11
(Tables 3 and 4). Their significance was much lower than
that of IL1 cluster and NOS3, and given the number of tests
performed, they are more likely to be false positives. The
IL1 cluster and NOS3 associations may also be due to type
1 errors and do not reach 5% statistical significance if
adjusted for the number of tests performed. However, for
Table 5: Joint effects of the IL1-CCC haplotype and other risk factors on CAD.
Trait Factor P_value Odds ratio 95 CI*
CAD IL1 CCC 0.047 1.22 1.00 1.47
Sex (baseline = fe-
male)
<0.001 4.86 4.00 5.91
Ever smoked <0.001 2.01 1.62 2.50
Hypertension <0.001 3.16 2.55 3.92
Overall test (4df) P < 0.0001
CAD before 50
years
IL1 CCC 0.002 1.53 1.17 2.01
Sex (baseline = fe-
male)
<0.001 6.44 4.78 8.67
Ever smoked <0.001 3.03 2.16 4.26
Hypertension <0.001 3.57 2.56 5.00
Overall test (4df) P < 0.0001
* 95% confidence interval (CI)
CAD, coronary artery disease.
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Page 11 of 12the IL1 gene cluster, the consistency with prior findings
[21,23,24,29,30] and the increased risk observed in younger
subjects increase the likelihood that this is a true associa-
tion, and the family-based design of our study provides
reassurance against confounding by population stratifica-
tion. Further investigation of a denser set of SNPs in this




BMI: body mass index; CABG: coronary artery bypass surgery; CAD: coronary
artery disease; CLR: conditional logistic regression; FBAT: family-based associa-
tion test; LD: linkage disequilibrium; LV: left ventricular; MI: myocardial infarc-
tion; PCR: polymerase chain reaction; PTCA: percutaneous transluminal
coronary angioplasty; SNP: single nucleotide polymorphism.
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